XADAGO safinamide

Drug Class

Monoamine oxidase B (MAO-B) inhibitor

Mechanism

Safinamide is a highly selective and reversible monoamine oxidase B (MAO-B) inhibitor that increases dopamine levels; it also modulates glutamate release and sodium/calcium channels.

Approved Indication

Adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing 'off' episodes.

What This Means For Patients

XADAGO is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2017) — Sources
• EMA — Approved (2015) — Sources
• NMPA — Approved (2025) — Sources

Pivotal Clinical Evidence

• SETTLE — Schapira et al., JAMA Neurol 2017 (NCT00627640) — Sources

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208583s000lbl.pdf
• https://www.ema.europa.eu/en/medicines/human/EPAR/xadago
• https://www.meiji.com/